Guardant Health appoints Dr. Manuel Hidalgo Medina to board effective July 17

Guardant Health, Inc.

Board increased to nine seats; Dr. Hidalgo appointed as Class II director, term expiring at 2026 annual meeting.
Dr. Hidalgo is Chief of Hematology/Medical Oncology at Weill Cornell Medicine and also serves on Bristol-Myers Squibb's board.
Received standard non-employee director compensation: stock option and RSU awards each valued at $362,500, vesting over four years.
Appointed to the nominating and corporate governance committee of the board.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Manuel Hidalgo Medina

Class II Director

GH · Guardant Health, Inc.

Effective: 2024-07-17
Filed: July 18, 2024, 7:59 PM ET

On July 17, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Manuel Hidalgo Medina, M.D., Ph.D., as a Class II director of the Company, to be effective as of July 17, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Manuel Hidalgo Medina was appointed as Class II Director at Guardant Health, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On July 17, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Manuel Hidalgo Medina, M.D., Ph.D., as a Class II director of the Company, to be effective as of July 17, 2024.

View on SEC.gov

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-181093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.